NEW YORK — This year’s HemOnc Today New York meeting included a session dedicated to treatment advances and challenges in melanoma
Speakers addressed genetic testing for high-risk patients, treatment for advanced disease and controversies in adjuvant therapy.
“A lively discussion point, as usual, was the choice between combination immunotherapy or monotherapy for patients with advanced, metastatic melanoma,” program co-chair Sanjiv S. Agarwala, MD, PhD, chief of medical oncology and hematology at St. Luke’s Cancer Center and professor of medicine at Temple University, told HemOnc Today. “That’s a debate that is not going away any time soon.”
Immunotherapy or targeted therapy in the frontline or adjuvant settings for patients with BRAF-positive disease also sparked interesting debate, Agarwala said.
“It was a very interesting discussion overall and we look forward to continuing it at future meetings,” said Agarwala, a HemOnc Today Editorial Board Member.
Disclosure: Agarwala reports consultant fees from Merck.